Get the Stockscreener App
0.255
3.41%
-0.009
After Hours:
.25
-0.005
-1.96%
Cellectar Biosciences Inc stock is traded at $0.255, with a volume of 212.67K.
It is down -3.41% in the last 24 hours and down -12.37% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$0.264
Open:
$0.265
24h Volume:
212.67K
Relative Volume:
0.23
Market Cap:
$11.75M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-0.0785
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
+2.37%
1M Performance:
-12.37%
6M Performance:
-83.44%
1Y Performance:
-91.61%
1-Day Range:
$0.248
$0.265
1-Week Range:
$0.241
$0.267
52-Week Range:
$0.224
$3.42
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
0.255 | 11.48M | 0 | -37.75M | -30.91M | -3.25 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
CVM Stock Offering Priced Below Previous Closing Value | CVM Sto - GuruFocus
CVM Stock Offering Priced Below Previous Closing Value | CVM Stock News - GuruFocus
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar signals Q3 EMA decision for conditional iopofosine approval while advancing pipeline and exploring strategic alternatives - MSN
Analysts Update Their Estimates For Cellectar Biosciences Inc - Stocksregister
Roth Capital Brokers Increase Earnings Estimates for CLRB - Defense World
Cellectar Biosciences’ (CLRB) “Hold” Rating Reiterated at Maxim Group - Defense World
Cellectar Biosciences Earnings Call: Progress Amid Challenges - TipRanks
Cellectar Biosciences (CLRB) Downgraded to 'Hold' by Maxim Group - GuruFocus
StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (CLRB) Downgraded Amid Strategic Uncertain - GuruFocus
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2025 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Inc (CLRB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Cellectar Biosciences Inc (CLRB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Cellectar Biosciences Reports Q1 2025 Financials and Strategic Plans - TipRanks
Transcript : Cellectar Biosciences, Inc., Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Cellectar Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CLRB Focuses on Advancing Radiotherapeutic Developments Amidst R - GuruFocus
Cellectar Biosciences Reports First Quarter 2025 Financial Resul - GuruFocus
Cellectar Biosciences, Inc. SEC 10-Q Report - TradingView
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
CLRB Financial Update: Cash Reserves Decline as of March 2025 | CLRB Stock News - GuruFocus
Cellectar Biosciences (CLRB) Expected to Announce Earnings on Tuesday - Defense World
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 | CLRB Stock News - GuruFocus
Cellectar Biosciences, Inc. to Report Q1 2025 Financial Results and Corporate Update on May 13, 2025 - Nasdaq
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 - GlobeNewswire
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on ... - Bluefield Daily Telegraph
JPMorgan Chase & Co. Has $55,000 Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated by Analysts at StockNews.com - Defense World
It makes sense and dollars to buy Cellectar Biosciences Inc (CLRB) stock - Sete News
Cellectar Biosciences (CLRB) Considers Strategic Options to Enha - GuruFocus
Cellectar Announces Plan to Explore Strategic Alternatives | CLR - GuruFocus
Cellectar Biosciences Inc (CLRB) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Checking in on Cellectar Biosciences Inc (CLRB) after recent insiders movement - knoxdaily.com
CLRB’s earnings estimates: Are they on track to meet expectations? - uspostnews.com
Cellectar explores strategic options to enhance shareholder value - Investing.com
Cellectar Announces Plan to Explore Strategic Alternatives - The Manila Times
Cellectar Explores Sale Options: Promising Cancer Drug Pipeline Attracts Strategic Review - Stock Titan
Immunic’s stock falls on multiple sclerosis data; Entrada’s layoffs - Endpoints News
Financial Metrics Unveiled: Cellectar Biosciences Inc (CLRB)’s Key Ratios in the Spotlight - DWinneX
Cellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Below 200-Day Moving Average – What’s Next? - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) versus Cellectar Biosciences (NASDAQ:CLRB) Financial Analysis - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World
Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):